pSivida Corp. (PSDV) Analysts See $-0.16 EPS; Esperion Therapeutics (ESPR) Sentiment Is 1.22

October 13, 2017 - By Adrian Erickson

Analysts expect pSivida Corp. (NASDAQ:PSDV) to report $-0.16 EPS on November, 6.They anticipate $0.05 EPS change or 23.81% from last quarter’s $-0.21 EPS. After having $-0.16 EPS previously, pSivida Corp.’s analysts see 0.00% EPS growth. About 854,228 shares traded or 41.84% up from the average. pSivida Corp. (NASDAQ:PSDV) has declined 20.28% since October 13, 2016 and is downtrending. It has underperformed by 36.98% the S&P500.

Esperion Therapeutics, Inc. is a lipid management company. The company has market cap of $1.39 billion. The Firm is a late-stage pharmaceutical firm focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . It currently has negative earnings. With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analysts await Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings on November, 2. They expect $-1.78 EPS, down 131.17% or $1.01 from last year’s $-0.77 per share. After $-1.92 actual EPS reported by Esperion Therapeutics Inc for the previous quarter, Wall Street now forecasts -7.29% EPS growth.

Ratings analysis reveals 0 of Esperion Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Esperion Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ESPR was included in 2 notes of analysts from November 14, 2016. The stock has “Neutral” rating by Citigroup on Monday, November 14. RBC Capital Markets maintained the shares of ESPR in report on Thursday, February 23 with “Sector Perform” rating.

Aisling Capital Llc holds 6.64% of its portfolio in Esperion Therapeutics Inc for 837,125 shares. Meditor Group Ltd owns 566,000 shares or 3.94% of their US portfolio. Moreover, Ra Capital Management Llc has 3.88% invested in the company for 731,531 shares. The New York-based Iguana Healthcare Management Llc has invested 2.62% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 363,347 shares.

About 177,352 shares traded. Esperion Therapeutics Inc (ESPR) has risen 133.75% since October 13, 2016 and is uptrending. It has outperformed by 117.05% the S&P500.

Investors sentiment increased to 1.23 in 2017 Q2. Its up 0.23, from 1 in 2017Q1. It improved, as 4 investors sold pSivida Corp. shares while 9 reduced holdings. 7 funds opened positions while 9 raised stakes. 5.76 million shares or 26.29% less from 7.81 million shares in 2017Q1 were reported. Barclays Public Ltd stated it has 33,188 shares. Millennium Limited Liability Company holds 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV) for 222,511 shares. One Trading Limited Partnership accumulated 28,633 shares. Blackrock holds 0% or 124,330 shares. Finemark Bank & Tru holds 71,800 shares or 0.01% of its portfolio. Pnc Grp Inc has 0% invested in pSivida Corp. (NASDAQ:PSDV). Susquehanna Grp Limited Liability Partnership stated it has 53,453 shares or 0% of all its holdings. Perceptive Limited Liability Company accumulated 1.15M shares. Vanguard, a Pennsylvania-based fund reported 1.10M shares. Tower Research Cap Ltd Liability Co (Trc) holds 0% or 100 shares in its portfolio. Jpmorgan Chase And has invested 0% in pSivida Corp. (NASDAQ:PSDV). Creative Planning reported 35,000 shares. Art Advsrs Lc stated it has 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV). Bridgeway Capital Management Incorporated accumulated 133,900 shares. Jacobs Levy Equity has 0.01% invested in pSivida Corp. (NASDAQ:PSDV) for 146,468 shares.

Among 5 analysts covering pSivida (NASDAQ:PSDV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. pSivida had 12 analyst reports since October 15, 2015 according to SRatingsIntel. The firm has “Buy” rating by Northland Capital given on Wednesday, June 14. H.C. Wainwright maintained it with “Buy” rating and $800 target in Tuesday, May 30 report. On Thursday, October 15 the stock rating was initiated by FBR Capital with “Outperform”. H.C. Wainwright maintained it with “Buy” rating and $5.0 target in Wednesday, October 11 report. The rating was maintained by H.C. Wainwright on Tuesday, July 11 with “Buy”. H.C. Wainwright maintained pSivida Corp. (NASDAQ:PSDV) rating on Tuesday, September 12. H.C. Wainwright has “Buy” rating and $5.0 target. The stock has “Buy” rating by FBR Capital on Tuesday, June 13. As per Friday, June 23, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $5.0 target in Wednesday, September 27 report. As per Tuesday, June 13, the company rating was maintained by Ladenburg.

Since June 14, 2017, it had 1 insider buy, and 0 sales for $99,962 activity. 56,700 shares were bought by Lurker Nancy, worth $99,962.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :